<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901393</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-CL-020</org_study_id>
    <nct_id>NCT01901393</nct_id>
  </id_info>
  <brief_title>Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery</brief_title>
  <official_title>A Multicenter, Prospective, Randomized, Double-blind Study to Determine the Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of intravenous ibuprofen compared to
      ketorolac for the treatment of postoperative pain as measured by patient pain intensity
      (Visual Analog Scale, VAS)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Pain Relief (Pain Intensity at Rest)</measure>
    <time_frame>First possible time post-surgery, an expected average of 6 hours</time_frame>
    <description>Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the &quot;No Pain&quot; anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Pain Relief (Pain Intensity With Movement)</measure>
    <time_frame>First possible time post-surgery, an expected average of 6 hours</time_frame>
    <description>Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the &quot;No Pain&quot; anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use in Post-operative Period</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <description>Amount of rescue medication (in milligrams) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of Rescue Med Will be Measured</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <description>Time to first rescue medication (in hours) in the postoperative period through discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <description>Measured using 2 question, 4 point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
    <description>Number of subjects experiencing treatment-emergent serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IV ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg ibuprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30mg ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV ibuprofen</intervention_name>
    <arm_group_label>IV ibuprofen</arm_group_label>
    <other_name>Caldolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <arm_group_label>ketorolac</arm_group_label>
    <other_name>Ketorolac Tromethamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for knee arthroscopy

        Exclusion Criteria:

          -  Inadequate IV access.

          -  History of allergy or hypersensitivity to any component of ibuprofen, ketorolac,
             aspirin (or aspirin related products), non-steroidal anti-inflammatory drugs (NSAIDs),
             opioids or cyclooxygenase-2 (COX-2) inhibitors.

          -  Less than 18 years of age.

          -  Use of analgesics less than 8 hours prior to surgery.

          -  Patients with active, clinically significant anemia.

          -  History or evidence of asthma or heart failure.

          -  Pregnant.

          -  Recent history of chronic opioid use.

          -  Concomitant use of probenecid.

          -  Inability to understand the requirements of the study, be willing to provide written
             informed consent (as evidenced by signature on an informed consent document approved
             by an Institutional Review Board [IRB]), and agree to abide by the study restrictions
             and to return for the required assessments.

          -  Refusal to provide written authorization for use and disclosure of protected health
             information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur P Wheeler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shrock Orthopedic Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Sports Medicine &amp; Orthopaedic Clinic</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Vexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <results_first_submitted>January 18, 2016</results_first_submitted>
  <results_first_submitted_qc>January 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2016</results_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post Operative Pain,</keyword>
  <keyword>Pail relief</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IV Ibuprofen</title>
          <description>800mg ibuprofen
IV ibuprofen</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac</title>
          <description>30mg ketorolac
Ketorolac</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat population consisted of all subjects who were enrolled and received at least a partial dose of investigational medicinal product.</population>
      <group_list>
        <group group_id="B1">
          <title>IV Ibuprofen</title>
          <description>800mg ibuprofen
IV ibuprofen</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac</title>
          <description>30mg ketorolac
Ketorolac</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="13.3"/>
                    <measurement group_id="B2" value="46" spread="15.5"/>
                    <measurement group_id="B3" value="46" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Pain Relief (Pain Intensity at Rest)</title>
        <description>Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the &quot;No Pain&quot; anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).</description>
        <time_frame>First possible time post-surgery, an expected average of 6 hours</time_frame>
        <population>This analysis was performed on all subject who completed the VAS at Rest Immediately Following their Procedure</population>
        <group_list>
          <group group_id="O1">
            <title>IV Ibuprofen</title>
            <description>800mg ibuprofen
IV ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30mg ketorolac
Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Pain Relief (Pain Intensity at Rest)</title>
          <description>Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the &quot;No Pain&quot; anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).</description>
          <population>This analysis was performed on all subject who completed the VAS at Rest Immediately Following their Procedure</population>
          <units>units on a scale (in mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="27.0"/>
                    <measurement group_id="O2" value="32" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use in Post-operative Period</title>
        <description>Amount of rescue medication (in milligrams) will be measured</description>
        <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Ibuprofen</title>
            <description>800mg ibuprofen
IV ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30mg ketorolac
Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use in Post-operative Period</title>
          <description>Amount of rescue medication (in milligrams) will be measured</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Narcotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="17.19"/>
                    <measurement group_id="O2" value="13.2" spread="16.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.5" spread="255.06"/>
                    <measurement group_id="O2" value="179.1" spread="248.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of Rescue Med Will be Measured</title>
        <description>Time to first rescue medication (in hours) in the postoperative period through discharge.</description>
        <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Ibuprofen</title>
            <description>800mg ibuprofen
IV ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30mg ketorolac
Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Rescue Med Will be Measured</title>
          <description>Time to first rescue medication (in hours) in the postoperative period through discharge.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.11"/>
                    <measurement group_id="O2" value="1.2" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Measured using 2 question, 4 point scale.</description>
        <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Ibuprofen</title>
            <description>800mg ibuprofen
IV ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30mg ketorolac
Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Measured using 2 question, 4 point scale.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Number of subjects experiencing treatment-emergent serious adverse events</description>
        <time_frame>Post-operative period until discharge, an expected average of 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Ibuprofen</title>
            <description>800mg ibuprofen
IV ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30mg ketorolac
Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Number of subjects experiencing treatment-emergent serious adverse events</description>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Pain Relief (Pain Intensity With Movement)</title>
        <description>Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the &quot;No Pain&quot; anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).</description>
        <time_frame>First possible time post-surgery, an expected average of 6 hours</time_frame>
        <population>This analysis was performed on all subject who completed the VAS with Movement Immediately Following their Procedure</population>
        <group_list>
          <group group_id="O1">
            <title>IV Ibuprofen</title>
            <description>800mg ibuprofen
IV ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30mg ketorolac
Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Pain Relief (Pain Intensity With Movement)</title>
          <description>Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the &quot;No Pain&quot; anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).</description>
          <population>This analysis was performed on all subject who completed the VAS with Movement Immediately Following their Procedure</population>
          <units>units on a scale (in mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="28.0"/>
                    <measurement group_id="O2" value="41" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IV Ibuprofen</title>
          <description>800mg ibuprofen
IV ibuprofen</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac</title>
          <description>30mg ketorolac
Ketorolac</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Rock, PhD</name_or_title>
      <organization>Cumberland Pharmaceutical Inc.</organization>
      <phone>615-255-0068</phone>
      <email>arock@cumberlandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

